Are We Too Reliant on Radiation Therapy for Children with Hodgkin’s Lymphoma?
Mené sur 587 patients pédiatriques atteints d'un lymphome hodgkinien à haut risque de récidive (âge : 2-21 ans ; durée médiane de suivi : 42,1 mois), cet essai multicentrique de phase III évalue l'efficacité, du point de vue de la survie sans événement, et la toxicité de l'ajout du brentuximab védotin à une chimiothérapie standard
The treatment of Hodgkin’s lymphoma is a success story that highlights our ability to cure cancer in advanced stages and when first-line therapy fails. Current goals focus on improving cure rates while mitigating the risk of long-term toxic effects that emerge during therapy and late effects that manifest after decades. Second cancers and cardiovascular complications are late effects that cause disease and death in patients who survived the initial cancer, but they may be relegated to secondary importance as compared with short-term disease control. Yet, the risk of second cancers continues to increase for at least 40 years after therapy, . . .
New England Journal of Medicine , éditorial, 2021